FRT1 Antibody

Potential Misidentification or Typographical Errors

• The term "FRT1" appears in yeast genetics (Saccharomyces Genome Database) as a gene involved in RNA transport and ribosomal subunit export ( ). No antibody targeting this yeast protein is described in the provided sources.

• FRT epithelial cells (female reproductive tract) are referenced in studies on innate immunity ( ), but these are cell types, not antibody targets.

• FRα (Folate Receptor alpha) is a validated therapeutic target in oncology, with anti-FRα antibodies like MOv18-IgG1 showing efficacy in restricting tumor growth in basal-like breast cancers ( ).

Anti-GPR40/FFAR1 (Extracellular) Antibody

• Target: GPR40/FFAR1 (Free Fatty Acid Receptor 1)

• Applications:

  • Western blot, immunohistochemistry, and flow cytometry ( ).

  • Species reactivity: Human, mouse, rat.

• Key Findings:

  • Detects FFAR1 in cerebellar Purkinje cells and molecular layers (rat brain) ( ).

  • Validated for cell-surface detection in human monocytic leukemia cells (THP-1) ( ).

Anti-Secreted Frizzled-Related Protein 1 (sFRP-1) Antibodies

• Target: sFRP-1 (Wnt/β-catenin pathway modulator)

• Applications:

  • Western blot, immunoprecipitation ( ).

• Key Findings:

  • 11 commercial sFRP-1 antibodies were screened; performance varied significantly between clones ( ).

  • Recommendations emphasize selecting antibodies validated via knockout cell line controls ( ).

Anti-Folate Receptor Alpha (FRα) Antibodies

• Target: FRα (overexpressed in TNBC and chemotherapy-resistant tumors)

• Therapeutic Use:

  • MOv18-IgG1 (anti-FRα antibody) conjugated with Src inhibitors restricts xenograft growth ( ).

  • Triggers immune-dependent cancer cell death via Fc-mediated effector functions ( ).

Technical Considerations for Antibody Development

• Antibody Formats:

  • Heterodimeric Fc platforms (e.g., Duobody, KiH) enable bispecific antibody engineering ( ).

  • IgG4-based antibodies undergo Fab arm exchange (FAE), enhancing therapeutic flexibility ( ).

• Reproducibility Challenges:

  • Standardized validation protocols (e.g., knockout cell lines) are critical for confirming antibody specificity ( ).

Recommended Alternatives for Further Investigation

If "FRT1 Antibody" refers to a novel or uncharacterized target, the following steps are advised:

1. Sequence Verification: Confirm the target’s UniProt/Swiss-Prot entry or homology to known proteins.

2. Epitope Characterization: Use phage display or hybridoma technology for antibody generation ( ).

3. Functional Assays: Validate via flow cytometry, immunofluorescence, or in vivo models ( ).